Precision Regimen for Personalized Pancreatic Cancer Therapy
Xiaoli Zhang,Jinming Yu,Min Li
DOI: https://doi.org/10.1002/pro6.19
2017-01-01
Precision Radiation Oncology
Abstract:Pancreatic cancer has the highest mortality rate of all cancer types worldwide.1 Surgery is the only curative treatment for pancreatic cancer, which is usually offered to patients diagnosed in the early stage. Chemotherapy and radiation therapy are given to patients with advanced pancreatic cancer who are not eligible for surgery. Gemcitabine or the combination agents FOLFIRINOX are still the first-line chemotherapeutic drugs for pancreatic cancer patients.2 However, pancreatic cancer patients are prone to developing chemoresistance in clinical practice, which renders the gemcitabine-based treatment ineffective. Nevertheless, the majority of pancreatic cancer patients respond poorly to radiation therapy.2 Immunotherapy has evolved as a new regimen for cancer treatment during the past decade, which stimulates the host immune system to fight the cancer. Immunotherapy has achieved great efficacy in lung cancer treatment; however, it has not shown much promise in pancreatic cancer therapy.3-5 To date, there are no US Food and Drug Administration-approved immunotherapies for metastatic pancreatic cancer, and they are still under investigation in clinical trials.6 In 2011, the concept of precision medicine was first proposed by the National Academy of Science, National Academy of Engineering, National Institute of Health and National Science Foundation in the USA, which shows great prospect in developing a new promising anti-tumor therapy, especially for such devastating diseases as pancreatic cancer.7 The definition of precision medicine, consistent with the principle of personalized medicine, refers to the medical care, which is especially achieved by using genetic or molecular profiling methods to detect the disease status, designed to optimize the efficiency or therapeutic benefit for particular groups of patients.8 Thus, precision medicine is the treatment targeted to the needs of an individual patient on the basis of various factors, such as genetic, biomarker, phenotypic, or psychosocial characteristics, which can minimize the unnecessary side-effects presented in standard therapy, reduce the toxicity, and improve clinical outcomes. The discovery of more sensitive biomarkers for early detection or radiation/chemotherapy resistance, and advances in imaging techniques for pancreatic cancer will provide powerful tools for specific and individualized therapy to treat pancreatic cancer patients. Little progress in pancreatic cancer therapy has been made in recent years, and there are still no effective treatments for this deadly disease. The 5-year survival rate for pancreatic cancer remains the lowest among all the common cancer types. The development of precision medicine could enlighten future research in pancreatic oncology. Until now, the etiology of pancreatic cancer has not been extensively explored, and great efforts need to be made to expand our knowledge on the development and progression of pancreatic cancer in order to obtain a comprehensive view. Genomic analysis on pancreatic cancer patients revealed core signaling pathways in human pancreatic cancer. Jones et al. carried out a genetic analysis of 24 pancreatic tumors passaged in vitro as cell lines or in nude mice, and for the first time observed an average of 63 genetic alterations, which defined a core set of 12 cellular signaling pathways.9 Functional predictions on these genetic alterations could provide more information on their roles played in pancreatic cancer progression. Precision medicine benefits from the development of biomarkers identification. Many potential therapeutic targets have been selected, and their functional roles in pancreatic cancer pathogenesis have been further explored using both in vitro and in vivo methods. Among them, zinc transporter ZIP4 has been validated as a promising target for pancreatic cancer therapy.10 ZIP4 is overexpressed in human pancreatic cancer, and promotes cell proliferation, invasion and migration, epithelial–mesenchymal transition, and angiogenesis by regulating a series of downstream signaling pathways, and interacting with other regulators including miRNA.11 ZIP4 knockdown significantly inhibits tumor growth and improves the pancreatic cancer survival.12 Thus, the evaluation on ZIP4 level in pancreatic cancer patients before and after surgery or chemo- and radiation therapy might help to guide the clinical individualized treatment. The study on the chemoresistance of pancreatic cancer showed that the expression levels of equilibrative and concentrative human nucleoside transporters, which transport gemcitabine across cell membrane to become effective in preventing DNA synthesis, can be used for predicting the clinical efficacy of gemcitabine in treating pancreatic cancer patients.13 It was reported that equilibrative human nucleoside transporter 1 protein expression is strongly correlated with pancreatic cancer patients’ survival with adjuvant gemcitabine treatment after surgery, and single-nucleotide polymorphisms from the equilibrative human nucleoside transporter 1 gene regulate the gene expression, which might exert additive effects when more than one single-nucleotide polymorphism is determined in this gene.14 Radiation resistance is also mediated by certain regulatory genes. For example, tumor-derived CC chemokine ligand 2 recruits Ly6C+CCR2+ monocytes to support tumor proliferation and neovascularization after radiotherapy, leading to the resistance to radiotherapy in pancreatic cancer patients.15 Precision medicine could optimize the chemo- and radiotherapy strategies, and enhance the therapeutic efficiency, which might bring a promising outcome in the treatment of pancreatic cancer. Further understanding and discovery of new biomarkers combined with advanced imaging techniques could provide an accurate personalized treatment plan based on the diagnosis during the evolutionary stages of pancreatic cancer, and reduce the side-effects found in traditional medicine, such as gemcitabine treatment. In the near future, with the accelerated development of precision medicine, this could be recommended as the first-line therapeutic option in clinical management of pancreatic cancer. At the same time, more efforts should be focused on the personalized therapeutic regimens based on the specific pathological characteristics plus specific molecular features and genetic profiling of individual patients. Furthermore, the safety and efficacy of the individualized treatments should be further validated in clinical trials with enhanced applications.